Better Health for All

Indivior's core business is dedicated to treating opioid use disorder (OUD) and overdose. Products like SUBLOCADE have demonstrated significant positive health impacts, with a study showing OUD patients treated with extended-release buprenorphine had 57% lower odds of all-cause emergency department visits compared to those receiving no medication.

OPVEE, an emergency opioid overdose treatment, received an $8.7 million order from BARDA for national preparedness. However, the company has faced substantial legal issues, including a $600 million settlement in 2020 for fraudulently promoting SUBOXONE Film as safer and less abuse-prone than similar drugs. This fraudulent promotion, along with allegations of illegally suppressing generic competition for Suboxone, led to additional settlements totaling over $500 million. The company's R&D expense decreased by 20% to $21 million in Q2'25, reflecting a refocusing on existing Phase 2 OUD assets. SUBLOCADE is available through a restricted program due to the serious risk of intravenous injection, and OPVEE has a range of adverse reactions including precipitation of opioid withdrawal and cardiovascular effects. Indivior states it works to break down barriers to treatment and promotes education to reduce stigma, but specific quantitative data on the reach or impact of these programs is not provided. The company's subsidiary pleaded guilty to making materially false statements relating to healthcare matters, and it entered into a five-year Corporate Integrity Agreement in 2020.

Fair Pay & Worker Respect

No specific, concrete data points for INDV.US related to any of the 'Fair Pay & Worker Respect' KPIs were found in the provided articles.

The articles discuss general industry trends, investor engagement themes, or data pertaining to other companies, but do not offer direct evidence for Indivior PLC's performance on these metrics.

Honest & Fair Business

The provided articles do not contain specific quantitative data or concrete facts required to assess Indivior PLC against any of the 'Honest & Fair Business' KPIs.

Information regarding regulatory fines, transparency index scores, details of whistleblower or anti-corruption policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, or third-party verification of ethical claims is explicitly stated as unavailable or not provided within the given texts.

Kind to Animals

No evidence was found in the provided articles to assess Indivior PLC against any of the 'Kind to Animals' KPIs. Information regarding animal testing policies, volumes, alternative testing usage, cruelty-free certifications, ethical sourcing, or animal welfare in operations was not available for Indivior PLC.

While some articles mentioned 'animal studies' in the context of drug development, no specific data points were provided to quantify the extent of animal testing or the use of alternatives.

No War, No Weapons

Indivior PLC is a pharmaceutical company focused on opioid dependence treatment.

The provided articles do not contain any specific, concrete data points related to revenue from arms or defense contracts, R&D in dual-use technologies, sales to embargoed regimes, peacebuilding investments, conflict divestment policies, board oversight of defense activities, export end-user certificates, lobbying for or against arms control, humanitarian procurement compliance, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, dual-use item screening, surveillance transparency, ethical red lines, exposure to controversial weapons, war risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace tech investment, or conflict zone procurement. Therefore, no KPIs can be scored based on the provided evidence.

Planet-Friendly Business

Indivior's total Scope 1, 2, and 3 greenhouse gas emissions were 114,548 tCO₂e in 2024, representing a 19.14% reduction from 141,671 tCO₂e in 2023.

The company has no SBTi-validated science-based carbon reduction targets, though it intends to set GHG targets aligned with the IPCC and Paris Agreement. A switch to more sustainable carton packaging for SUBOXONE Film in the U.S. is expected to reduce GHG emissions by 60% per carton in 2024. The Hull Fine Chemical Plant (FCP) holds ISO14001:2015 certification and operates under an Environmental Permit, with no material breaches of compliance reported in 2023. Indivior includes climate change strategy, governance, risks, and metrics in its TCFD statement and conducts qualitative and quantitative climate scenario analyses.

Respect for Cultures & Communities

The provided articles do not contain specific, concrete data points for any of the KPIs related to 'Respect for Cultures & Communities'. Article 0 explicitly notes "Limited quantitative data on community engagement, FPIC participation, grievance mechanisms, or cultural preservation investments" and "No data on local procurement spending or indigenous supplier engagement."

Article 1 mentions research on treatment barriers for American Indian/Alaska Native (AI/AN) populations but states it "does not provide data on Indivior's specific actions to address these cultural and community concerns." No other articles provide relevant quantitative or qualitative evidence for the defined KPIs.

Safe & Smart Tech

The company has not experienced any material cybersecurity incidents to date and aligns its information security program with the NIST 800-53 CSF framework, conducting periodic internal and external audits and assessments.

The Audit & Risk Committee oversees cybersecurity efforts, receiving annual updates from the Chief Information and Innovation Officer and Chief Information Security Officer. However, Indivior PLC entered into a 2020 Resolution Agreement with the DOJ, FTC, and US State Attorneys General, resolving criminal and civil liability related to marketing and promotional practices, which included $600 million in payments and a wholly owned subsidiary pleading guilty to a false statement. The company also has ongoing compliance and reporting obligations under a Corporate Integrity Agreement and an FTC Stipulated Order. Its privacy policy outlines user rights such as access, correction, erasure, and the right to opt out of sales/sharing/targeted advertising. Data is retained as long as reasonably necessary for collection purposes, including legal, regulatory, tax, accounting, or reporting requirements, and may be retained longer for complaints or potential litigation. The company states it invests in ongoing employee training and awareness programs and conducts security testing, including incident simulations.